Canada Markets close in 1 hr 19 mins

Novartis AG (NVSEF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
85.400.00 (0.00%)
As of 09:30AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close85.40
Open85.40
Bid0.00 x 0
Ask0.00 x 0
Day's Range85.40 - 85.40
52 Week Range78.78 - 95.00
Volume40,448
Avg. Volume42,988
Market Cap191.364B
Beta (5Y Monthly)0.55
PE Ratio (TTM)19.73
EPS (TTM)4.33
Earnings DateN/A
Forward Dividend & Yield3.35 (3.87%)
Ex-Dividend DateMar 08, 2022
1y Target EstN/A
  • GlobeNewswire

    Novartis Cosentyx® (secukinumab) receives positive CHMP opinion for expanded use in childhood arthritic conditions

    Positive opinion could expand the role of Cosentyx® (secukinumab) in reducing flare risk in pediatric enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) patients in the EUSafety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indicationsSince its initial approval, Cosentyx has a proven sustained efficacy profile across several systemic inflammatory conditions and has treated more than 700,000 patients worldwide 1-11 Ba

  • Reuters

    CORRECTED-Cancer coalition aims to boost access to medicines in poorer countries

    Pharmaceutical companies including Novartis and Roche have teamed up with global cancer organisations in an alliance aimed at getting more oncology medications to poorer countries. Currently, fewer than 50% of the cancer drugs on the World Health Organization's (WHO) essential medicines list are available in low and middle income countries, and the disease burden is growing. Without action, almost three in four cancer deaths are set to occur in these settings in the next decade.

  • Zacks

    Alnylam's (ALNY) Marketed Drugs Aid Growth Amid Competition

    Alnylam's (ALNY) portfolio of approved drugs is witnessing strong uptake so far while its pipeline is progressing well. However, stiff competition in the target market remains a woe.